Gain of 1q is a marker of poor prognosis in Wilms' tumors

Genes Chromosomes and Cancer

Volumn 52, Issue 11, 2013, Pages 1065-1074

  Segers, H ^a   van den Heuvel Eibrink, M M ^a   Williams, R D ^b   van Tinteren, H ^c   Vujanic, G ^d   Pieters, R ^a   Pritchard Jones, K ^b,e   Bown, N ^f  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER;

ADOLESCENT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHILD; CHROMOSOME 14Q; CHROMOSOME 16Q; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CONTROLLED STUDY; EVENT FREE SURVIVAL; FOLLOW UP; GENETIC ASSOCIATION; HAZARD RATIO; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; ONSET AGE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHOOL CHILD; UNITED KINGDOM;

EID: 84884704621     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22101     Document Type: Article

References (50)

1. Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Benard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJL, Potschger U, Ambros PF. 2011. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 17:792-804.
2. Beckwith JB, Palmer NF. 1978. Histopathology and prognosis of Wilms tumors: Results from the First National Wilms' Tumor Study. Cancer 41:1937-1948.
3. Bown N, Cotterill SJ, Roberts P, Griffiths M, Larkins S, Hibbert S, Middleton H, Kelsey A, Tritton D, Mitchell C. 2002. Cytogenetic abnormalities and clinical outcome in Wilms tumor: A study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 38:11-21.
4. Breslow N, Olshan A, Beckwith JB, Green DM. 1993. Epidemiology of Wilms tumor. Med Pediatr Oncol 21:172-181.
5. de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF. 2004. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): A randomised controlled trial. Lancet 364:1229-1235.
6. Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, Haase GM, Coppes MJ, Coccia P, Kletzel M, Weetman RM, Donaldson M, Macklis RM, Green DM. 2006. Treatment of anaplastic histology Wilms' tumor: Results from the fifth National Wilms' Tumor Study. J Clin Oncol 24:2352-2358.
7. Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, Gratias EJ, Dix DB, Ehrlich PF, Khanna G, et al. 2013. Children's Oncology Group's 2013 blueprint for research: Renal tumors. Pediatr Blood Cancer 60:994-1000.
8. Faria P, Beckwith JB, Mishra K, Zuppan C, Weeks DA, Breslow N, Green DM. 1996. Focal versus diffuse anaplasia in Wilms tumor-New definitions with prognostic significance: A report from the National Wilms Tumor Study Group. Am J Surg Pathol 20:909-920.
9. Goeman JJ. 2010. L1 penalized estimation in the Cox proportional hazards model. Biom J 52:70-84.
10. Gow KW, Murphy JJ. 2002. Cytogenetic and histologic findings in Wilms' tumor. J Pediatr Surg 37:823-827.
11. Green DM. 2004. The treatment of stages I-IV favorable histology Wilms' tumor. J Clin Oncol 22:1366-1372.
12. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. 1994. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 54:2331-2333.
13. Grundy RG, Pritchard J, Scambler P, Cowell JK. 1998. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. Br J Cancer 78:1181-1187.
14. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM; National Wilms Tumor Study Group. 2005. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312-7321.
15. Hawthorn L, Cowell JK. 2011. Analysis of Wilms' tumors using SNP mapping array-based comparative genomic hybridization. PLoS One 6:e18941.
16. Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholson J, Grundy P, Grundy R, Gessler M, Shipley J, Pritchard-Jones K. 2001. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 158:393-398.
17. Hoglund M, Gisselsson D, Hansen GB, Mitelman F. 2004. Wilms tumors develop through two distinct karyotypic pathways. Cancer Genet Cytogenet 150:9-15.
18. Huang CC, Gadd S, Breslow N, Cutcliffe C, Sredni ST, Helenowski IB, Dome JS, Grundy PE, Green DM, Fritsch MK, Perlman EJ. 2009. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: A report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res 15:1770-1778.
19. Kalapurakal JA, Dome JS, Perlman EJ, Malogolowkin M, Haase GM, Grundy P, Coppes MJ. 2004. Management of Wilms' tumour: Current practice and future goals. Lancet Oncol 5:37-46.
20. Kaneko Y, Homma C, Maseki N, Sakurai M, Hata J. 1991. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors. Cancer Res 51:5937-5942.
21. Klamt B, Schulze M, Thate C, Mares J, Goetz P, Kodet R, Scheulen W, Weirich A, Graf N, Gessler M. 1998. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer 22:287-294.
22. Kullendorff CM, Soller M, Wiebe T, Mertens F. 2003. Cytogenetic findings and clinical course in a consecutive series of Wilms tumors. Cancer Genet Cytogenet 140:82-87.
23. Lu YJ, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K. 2002. Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 360:385-386.
24. Mathew P, Douglass EC, Jones D, Valentine M, Valentine V, Rowe S, Shapiro DN. 1996. Der(16)t(1;16)(q21;q13) in Wilms' tumor: Friend or foe. Med Pediatr Oncol 27:3-7.
25. MdZin R, Murch A, Charles A. 2010. Cytogenetic findings in Wilms' tumour: A single institute study. Pathology 42:643-649.
26. Messahel B, Williams R, Ridolfi A, A'Hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, Kelsey A, Sebire N, Jones C, Vujanic G, Pritchard-Jones K, On behalf of the Children's Cancer and Leukaemia Group (CCLG). 2009. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: A Children's Cancer and Leukaemia Group (CCLG) Study. Eur J Cancer 45:819-826.
27. Metzger ML, Dome JS. 2005. Current therapy for Wilms' tumor. Oncologist 10:815-826.
28. Mitchell C, Jones PM, Kelsey A, Vujanic GM, Marsden B, Shannon R, Gornall P, Owens C, Taylor R, Imeson J, Middelton H, Pritchard J. 2000. The treatment of Wilms' tumour: Results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study. Br J Cancer 83:602-608.
29. Mitchell C, Pritchard-Jones K, Shannon R, Hutton C, Stevens S, Machin D, Imeson J, Kelsey A, Vujanic GM, Gornall P, Walker J, Taylor R, Sartori P, Hale J, Levitt G, Messahel B, Middleton H, Grundy R, Pritchard J, For the United Kingdom Cancer Study Group. 2006. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: Results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer 42:2554-2562.
30. Mitelman F, Johansson B, Mertens F, editors. 2012. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Available from: http://cgap.nci.nih.gov.ezp-prod1.hul.harvard.edu/Chromosomes/Mitelman.
31. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovery O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, Jones C. 2006. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 210:49-58.
32. Natrajan R, Little SE, Sodha N, Reis-Filho JS, Mackay A, Fenwick K, Ashworth A, Perlman EJ, Dome JS, Grundy PE, Pritchard-Jones K, Jones C. 2007. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 211:52-59.
33. Perotti D, Spreafico F, Torri F, Gamba B, D'Adamo P, Pizzamiglio S, Terenziani M, Catania S, Collini P, Nantron M, Pession A, Bianchi M, Indolfi P, D'Angelo P, Fossati-Bellani F, Verderio P, Macciardi F, Radice P. 2012. Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse. Genes Chromosomes Cancer 51:644-653.
34. Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, Hutton C, Mitchell C. 2003. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: A study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. J Clin Oncol 21:3269-3275.
35. Pritchard-Jones K, Moroz V, Vujanic G, Powis M, Walker J, Messahel B, Hobson R, Levitt G, Kelsey A, Mitchell C. 2012. Treatment and outcome of Wilms' tumour patients: An analysis of all cases registered in the UKW3 trial. Ann Oncol 23:2457-2463.
36. Shaffer LG, Tommerup N. 2005. An International System for Human Cytogenetic Nomenclature (2005). Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: Karger.
37. Sheng WW, Soukup S, Bove K, Gotwals B, Lampkin B. 1990. Chromosome analysis of 31 Wilms' tumors. Cancer Res 50:2786-2793.
38. Slater RM, Mannens MM. 1992. Cytogenetics and molecular genetics of Wilms' tumor of childhood. Cancer Genet Cytogenet 61:111-121.
39. Smets AM, van Tinteren H, Bergeron C, De Camargo B, Graf N, Pritchard-Jones K, de Kraker J. 2012. The contribution of chest CT-scan at diagnosis in children with unilateral Wilms' tumour. Results of the SIOP 2001 study. Eur J Cancer 48:1060-1065.
40. Spreafico F, Pritchard Jones K, Malogolowkin MH, Bergeron C, Hale J, de Kraker J, Dallorso S, Acha T, de Camargo B, Dome JS, Graf N. 2009. Treatment of relapsed Wilms tumors: Lessons learned. Expert Rev Anticancer Ther 9:1807-1815.
41. Spreafico F, Gamba B, Mariani L, Collini P, D'Angelo P, Pession A, Di Cataldo A, Indolfi P, Nantron M, Terenziani M, Morosi C, Radice P, Perotti D; AIEOP Wilms Tumor Working Group. 2013. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: A study from the Italian Association of Pediatric Hematology and Oncology. J Urol 189:260-266.
42. Tournade MF, Com-Nougue C, de Kraker J, Ludwig R, Rey A, Burgers JM, Sandstedt B, Godzinski J, Carli M, Potter R, Zucker JM; International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee. 2001. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: Results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 19:488-500.
43. Vujanic GM, Harms D, Sandstedt B, Weirich A, de Kraker J, Delemarre JF. 1999. New definitions of focal and diffuse anaplasia in Wilms tumor: The International Society of Paediatric Oncology (SIOP) experience. Med Pediatr Oncol 32:317-323.
44. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J. 2002. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38:79-82.
45. Vujanic GM, Sandstedt B, Kelsey A, Sebire NJ. 2009. Central pathology review in multicenter trials and studies: Lessons from the nephroblastoma trials. Cancer 115:1977-1983.
46. Weirich A, Ludwig R, Graf N, Abel U, Leuschner I, Vujanic GM, Mehls O, Boos J, Beck J, Royer-Pokora B, Voute PA. 2004. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann Oncol 15:808-820.
47. Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K; Children's Cancer and Leukaemia Group; SIOP Wilms Tumour Biology Group. 2010. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 16:2036-2045.
48. Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K. 2011. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer 50:982-995.
49. Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M. 2007. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer 46:163-170.
50. Zin R, Pham K, Ashleigh M, Ravine D, Waring P, Charles A. 2012. SNP-based arrays complement classic cytogenetics in the detection of chromosomal aberrations in Wilms' tumor. Cancer Genet 205:80-93.